TY - JOUR T1 - Ferroptosis and kidney disease JO - Nefrología (English Edition) T2 - AU - Martin-Sanchez,Diego AU - Fontecha-Barriuso,Miguel AU - Martinez-Moreno,Julio M. AU - Ramos,Adrian M. AU - Sanchez-Niño,Maria D. AU - Guerrero-Hue,Melania AU - Moreno,Juan A. AU - Ortiz,Alberto AU - Sanz,Ana B. SN - 20132514 M3 - 10.1016/j.nefroe.2020.09.006 DO - 10.1016/j.nefroe.2020.09.006 UR - https://www.revistanefrologia.com/en-ferroptosis-kidney-disease-articulo-S2013251420300985 AB - Cell death is a finely regulated process occurring through different pathways. Regulated cell death, either through apoptosis or regulated necrosis offers the possibility of therapeutic intervention. Necroptosis and ferroptosis are among the best studied forms of regulated necrosis in the context of kidney disease. We now review the current evidence supporting a role for ferroptosis in kidney disease and the implications of this knowledge for the design of novel therapeutic strategies. Ferroptosis is defined functionally, as a cell modality characterized by peroxidation of certain lipids, constitutively suppressed by GPX4 and inhibited by iron chelators and lipophilic antioxidants. There is functional evidence of the involvement of ferroptosis in diverse forms of kidneys disease. In a well characterized nephrotoxic acute kidney injury model, ferroptosis caused an initial wave of death, triggering an inflammatory response that in turn promoted necroptotic cell death that perpetuated kidney dysfunction. This suggests that ferroptosis inhibitors may be explored as prophylactic agents in clinical nephrotoxicity or ischemia–reperfusion injury such as during kidney transplantation. Transplantation offers the unique opportunity of using anti-ferroptosis agent ex vivo, thus avoiding bioavailability and in vivo pharmacokinetics and pharmacodynamics issues. ER -